BRCA1 and ovarian carcinoma: Kluska et al. recently proposed that the testing panel of Polish founder mutations be expanded to include two new mutations, c.1687C > T in BRCA1 and c.9371A > T in BRCA2 with the status pathogenic and likely pathogenic respectively, which showed strong founder effects in Polish patients with familial or early-onset breast and/or ovarian cancer [25].